MedTrace Logo

Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

NCT02807285 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2017-09-07

No results posted yet for this study

Summary

The primary objective of this expanded access program is to provide ocrelizumab as treatment for eligible participants with primary progressive multiple sclerosis (PPMS) before it is commercially available in the United States (U.S.) for the indication of PPMS.

Conditions

Interventions

DRUG

Ocrelizumab

Participants will receive 600 mg ocrelizumab as two 300 mg infusions separated by 14 days, every 24 weeks.

Sponsors & Collaborators

  • Genentech, Inc.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02807285 on ClinicalTrials.gov